JP2011515078A - ＳＰＡＲＣ特異的ｍｉＲＮＡを使用する、治療、診断、及び拮抗物質発見方法 - Google Patents

Info

Publication number

JP2011515078A

JP2011515078A JP2010549777A JP2010549777A JP2011515078A JP 2011515078 A JP2011515078 A JP 2011515078A JP 2010549777 A JP2010549777 A JP 2010549777A JP 2010549777 A JP2010549777 A JP 2010549777A JP 2011515078 A JP2011515078 A JP 2011515078A

Authority

JP

Japan

Prior art keywords

cancer

mirna

nucleic acid

sparc

expression

Prior art date

2008-03-01

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002679 microRNA Substances 0.000 title claims abstract description 291
• 108091070501 miRNA Proteins 0.000 title claims abstract description 244
• 238000000034 method Methods 0.000 title claims abstract description 134
• 238000011282 treatment Methods 0.000 title claims description 32
• 239000005557 antagonist Substances 0.000 title claims description 8
• 238000003745 diagnosis Methods 0.000 title 1
• 150000007523 nucleic acids Chemical class 0.000 claims abstract description 172
• 102000039446 nucleic acids Human genes 0.000 claims abstract description 160
• 108020004707 nucleic acids Proteins 0.000 claims abstract description 160
• 239000000203 mixture Substances 0.000 claims abstract description 101
• 239000012634 fragment Substances 0.000 claims abstract description 12
• 108091007428 primary miRNA Proteins 0.000 claims abstract description 12
• 230000014509 gene expression Effects 0.000 claims description 171
• 210000004027 cell Anatomy 0.000 claims description 135
• 108090000623 proteins and genes Proteins 0.000 claims description 82
• 206010028980 Neoplasm Diseases 0.000 claims description 79
• 201000011510 cancer Diseases 0.000 claims description 64
• 102000004169 proteins and genes Human genes 0.000 claims description 51
• 238000001727 in vivo Methods 0.000 claims description 44
• 108020004999 messenger RNA Proteins 0.000 claims description 43
• 125000003729 nucleotide group Chemical group 0.000 claims description 39
• 239000002773 nucleotide Substances 0.000 claims description 38
• 210000001519 tissue Anatomy 0.000 claims description 38
• 230000001225 therapeutic effect Effects 0.000 claims description 35
• 230000000694 effects Effects 0.000 claims description 34
• 201000010099 disease Diseases 0.000 claims description 31
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
• 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 27
• 239000013598 vector Substances 0.000 claims description 27
• 230000002062 proliferating effect Effects 0.000 claims description 25
• 208000037803 restenosis Diseases 0.000 claims description 24
• 230000002401 inhibitory effect Effects 0.000 claims description 22
• 108700008625 Reporter Genes Proteins 0.000 claims description 19
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 19
• 238000001890 transfection Methods 0.000 claims description 19
• 108091036066 Three prime untranslated region Proteins 0.000 claims description 18
• 108060001084 Luciferase Proteins 0.000 claims description 17
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 17
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
• 230000003042 antagnostic effect Effects 0.000 claims description 15
• 230000005764 inhibitory process Effects 0.000 claims description 15
• 241000700605 Viruses Species 0.000 claims description 14
• 230000000295 complement effect Effects 0.000 claims description 14
• 230000001965 increasing effect Effects 0.000 claims description 14
• 239000013612 plasmid Substances 0.000 claims description 14
• 229920001184 polypeptide Polymers 0.000 claims description 14
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 13
• 229920000642 polymer Polymers 0.000 claims description 13
• 206010033128 Ovarian cancer Diseases 0.000 claims description 12
• 210000003527 eukaryotic cell Anatomy 0.000 claims description 12
• 238000011144 upstream manufacturing Methods 0.000 claims description 12
• 239000003623 enhancer Substances 0.000 claims description 11
• 238000004519 manufacturing process Methods 0.000 claims description 11
• 206010006187 Breast cancer Diseases 0.000 claims description 10
• 208000026310 Breast neoplasm Diseases 0.000 claims description 10
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 10
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
• 201000005202 lung cancer Diseases 0.000 claims description 10
• 208000020816 lung neoplasm Diseases 0.000 claims description 10
• 230000002265 prevention Effects 0.000 claims description 10
• 235000012000 cholesterol Nutrition 0.000 claims description 9
• 206010020718 hyperplasia Diseases 0.000 claims description 9
• 239000002502 liposome Substances 0.000 claims description 9
• 238000013518 transcription Methods 0.000 claims description 9
• 230000035897 transcription Effects 0.000 claims description 9
• 230000029663 wound healing Effects 0.000 claims description 9
• 206010005003 Bladder cancer Diseases 0.000 claims description 8
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 8
• 108091068956 Homo sapiens miR-186 stem-loop Proteins 0.000 claims description 8
• 206010060862 Prostate cancer Diseases 0.000 claims description 8
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims description 8
• ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 8
• 238000002512 chemotherapy Methods 0.000 claims description 8
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 8
• 206010009944 Colon cancer Diseases 0.000 claims description 7
• 206010025323 Lymphomas Diseases 0.000 claims description 7
• 208000003445 Mouth Neoplasms Diseases 0.000 claims description 7
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 7
• 206010039491 Sarcoma Diseases 0.000 claims description 7
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 7
• 230000027455 binding Effects 0.000 claims description 7
• 238000001794 hormone therapy Methods 0.000 claims description 7
• 238000009169 immunotherapy Methods 0.000 claims description 7
• 238000002647 laser therapy Methods 0.000 claims description 7
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 7
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 7
• 201000002528 pancreatic cancer Diseases 0.000 claims description 7
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 7
• 238000001959 radiotherapy Methods 0.000 claims description 7
• 230000002441 reversible effect Effects 0.000 claims description 7
• 201000000849 skin cancer Diseases 0.000 claims description 7
• 238000001356 surgical procedure Methods 0.000 claims description 7
• 201000002510 thyroid cancer Diseases 0.000 claims description 7
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
• 102000003780 Clusterin Human genes 0.000 claims description 6
• 108090000197 Clusterin Proteins 0.000 claims description 6
• 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
• 206010020843 Hyperthermia Diseases 0.000 claims description 6
• 208000034578 Multiple myelomas Diseases 0.000 claims description 6
• 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
• 102100028255 Renin Human genes 0.000 claims description 6
• 108090000783 Renin Proteins 0.000 claims description 6
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 6
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
• 238000003556 assay Methods 0.000 claims description 6
• 201000010881 cervical cancer Diseases 0.000 claims description 6
• 208000029742 colonic neoplasm Diseases 0.000 claims description 6
• 201000004101 esophageal cancer Diseases 0.000 claims description 6
• 206010017758 gastric cancer Diseases 0.000 claims description 6
• 201000010536 head and neck cancer Diseases 0.000 claims description 6
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
• 230000036031 hyperthermia Effects 0.000 claims description 6
• 238000001990 intravenous administration Methods 0.000 claims description 6
• 208000032839 leukemia Diseases 0.000 claims description 6
• 201000007270 liver cancer Diseases 0.000 claims description 6
• 208000014018 liver neoplasm Diseases 0.000 claims description 6
• 201000008968 osteosarcoma Diseases 0.000 claims description 6
• 201000011549 stomach cancer Diseases 0.000 claims description 6
• 238000007920 subcutaneous administration Methods 0.000 claims description 6
• 230000002792 vascular Effects 0.000 claims description 6
• 102000007469 Actins Human genes 0.000 claims description 5
• 108010085238 Actins Proteins 0.000 claims description 5
• 208000022211 Arteriovenous Malformations Diseases 0.000 claims description 5
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
• 208000002260 Keloid Diseases 0.000 claims description 5
• 206010023330 Keloid scar Diseases 0.000 claims description 5
• 108091093037 Peptide nucleic acid Proteins 0.000 claims description 5
• 201000004681 Psoriasis Diseases 0.000 claims description 5
• 206010039710 Scleroderma Diseases 0.000 claims description 5
• 208000024313 Testicular Neoplasms Diseases 0.000 claims description 5
• 206010057644 Testis cancer Diseases 0.000 claims description 5
• 201000003790 Weaver syndrome Diseases 0.000 claims description 5
• 239000000853 adhesive Substances 0.000 claims description 5
• 230000001070 adhesive effect Effects 0.000 claims description 5
• 230000005744 arteriovenous malformation Effects 0.000 claims description 5
• 208000029078 coronary artery disease Diseases 0.000 claims description 5
• 210000004696 endometrium Anatomy 0.000 claims description 5
• 230000001969 hypertrophic effect Effects 0.000 claims description 5
• 201000001371 inclusion conjunctivitis Diseases 0.000 claims description 5
• 238000007918 intramuscular administration Methods 0.000 claims description 5
• 238000007912 intraperitoneal administration Methods 0.000 claims description 5
• 210000001117 keloid Anatomy 0.000 claims description 5
• 208000007106 menorrhagia Diseases 0.000 claims description 5
• 201000007914 proliferative diabetic retinopathy Diseases 0.000 claims description 5
• 230000004044 response Effects 0.000 claims description 5
• 238000003757 reverse transcription PCR Methods 0.000 claims description 5
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
• 231100000241 scar Toxicity 0.000 claims description 5
• 201000003120 testicular cancer Diseases 0.000 claims description 5
• 206010044325 trachoma Diseases 0.000 claims description 5
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims description 4
• 108010035532 Collagen Proteins 0.000 claims description 4
• 102000008186 Collagen Human genes 0.000 claims description 4
• 206010061818 Disease progression Diseases 0.000 claims description 4
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims description 4
• 229920001436 collagen Polymers 0.000 claims description 4
• 230000003111 delayed effect Effects 0.000 claims description 4
• 230000005750 disease progression Effects 0.000 claims description 4
• 238000002493 microarray Methods 0.000 claims description 4
• 239000002105 nanoparticle Substances 0.000 claims description 4
• 239000000126 substance Substances 0.000 claims description 4
• RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 4
• 229940104230 thymidine Drugs 0.000 claims description 4
• 229940035893 uracil Drugs 0.000 claims description 4
• 102000000905 Cadherin Human genes 0.000 claims description 3
• 108050007957 Cadherin Proteins 0.000 claims description 3
• 102100036213 Collagen alpha-2(I) chain Human genes 0.000 claims description 3
• 208000031220 Hemophilia Diseases 0.000 claims description 3
• 208000009292 Hemophilia A Diseases 0.000 claims description 3
• 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 claims description 3
• 102000011782 Keratins Human genes 0.000 claims description 3
• 108010076876 Keratins Proteins 0.000 claims description 3
• 108050000637 N-cadherin Proteins 0.000 claims description 3
• 108010012822 Peroxiredoxin III Proteins 0.000 claims description 3
• 101710120473 Tubulin beta-5 chain Proteins 0.000 claims description 3
• 238000001514 detection method Methods 0.000 claims description 3
• 108090001030 Lipoproteins Proteins 0.000 claims description 2
• 102000004895 Lipoproteins Human genes 0.000 claims description 2
• 108091067517 Mus musculus miR-377 stem-loop Proteins 0.000 claims description 2
• 108091064002 Rattus norvegicus miR-377 stem-loop Proteins 0.000 claims description 2
• 239000000090 biomarker Substances 0.000 claims description 2
• 238000010606 normalization Methods 0.000 claims description 2
• 150000003384 small molecules Chemical group 0.000 claims description 2
• 210000004507 artificial chromosome Anatomy 0.000 claims 5
• 208000009458 Carcinoma in Situ Diseases 0.000 claims 4
• 201000000274 Carcinosarcoma Diseases 0.000 claims 4
• 206010072558 Carotid artery restenosis Diseases 0.000 claims 4
• 206010056489 Coronary artery restenosis Diseases 0.000 claims 4
• 201000009273 Endometriosis Diseases 0.000 claims 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims 4
• 208000001132 Osteoporosis Diseases 0.000 claims 4
• 206010072557 Peripheral artery restenosis Diseases 0.000 claims 4
• 206010037649 Pyogenic granuloma Diseases 0.000 claims 4
• 210000001627 cerebral artery Anatomy 0.000 claims 4
• 210000001105 femoral artery Anatomy 0.000 claims 4
• 201000004933 in situ carcinoma Diseases 0.000 claims 4
• 208000003154 papilloma Diseases 0.000 claims 4
• 208000002815 pulmonary hypertension Diseases 0.000 claims 4
• 210000002254 renal artery Anatomy 0.000 claims 4
• 229920002873 Polyethylenimine Polymers 0.000 claims 3
• 206010003210 Arteriosclerosis Diseases 0.000 claims 2
• 108010085220 Multiprotein Complexes Proteins 0.000 claims 2
• 102000007474 Multiprotein Complexes Human genes 0.000 claims 2
• 108091061960 Naked DNA Proteins 0.000 claims 2
• 102000019202 Peroxiredoxin III Human genes 0.000 claims 2
• 230000001028 anti-proliverative effect Effects 0.000 claims 2
• 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
• 108091061666 Homo sapiens miR-542 stem-loop Proteins 0.000 claims 1
• 238000004949 mass spectrometry Methods 0.000 claims 1
• 238000000015 thermotherapy Methods 0.000 claims 1
• 230000001105 regulatory effect Effects 0.000 abstract description 22
• 230000004071 biological effect Effects 0.000 abstract description 5
• 101000881168 Homo sapiens SPARC Proteins 0.000 abstract description 2
• 102000045436 human SPARC Human genes 0.000 abstract description 2
• 238000009472 formulation Methods 0.000 description 40
• -1 hsa-miR-125b Proteins 0.000 description 36
• 108700011259 MicroRNAs Proteins 0.000 description 27
• 235000018102 proteins Nutrition 0.000 description 26
• 230000009467 reduction Effects 0.000 description 26
• 108020005345 3' Untranslated Regions Proteins 0.000 description 24
• 108020004414 DNA Proteins 0.000 description 24
• 239000005089 Luciferase Substances 0.000 description 16
• 208000024891 symptom Diseases 0.000 description 16
• 238000002703 mutagenesis Methods 0.000 description 13
• 231100000350 mutagenesis Toxicity 0.000 description 13
• 239000003814 drug Substances 0.000 description 12
• 238000009396 hybridization Methods 0.000 description 11
• 238000003780 insertion Methods 0.000 description 11
• 230000037431 insertion Effects 0.000 description 11
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 10
• 210000004881 tumor cell Anatomy 0.000 description 10
• 108091070512 Homo sapiens let-7d stem-loop Proteins 0.000 description 9
• 241001465754 Metazoa Species 0.000 description 9
• 239000002299 complementary DNA Substances 0.000 description 9
• 238000000338 in vitro Methods 0.000 description 9
• 230000008569 process Effects 0.000 description 9
• 241000699666 Mus <mouse, genus> Species 0.000 description 8
• 230000033115 angiogenesis Effects 0.000 description 8
• 238000012217 deletion Methods 0.000 description 8
• 230000037430 deletion Effects 0.000 description 8
• 229940079593 drug Drugs 0.000 description 8
• 239000011159 matrix material Substances 0.000 description 8
• 239000000523 sample Substances 0.000 description 8
• 108091026890 Coding region Proteins 0.000 description 7
• 108091069047 Homo sapiens let-7i stem-loop Proteins 0.000 description 7
• 108091067471 Homo sapiens miR-211 stem-loop Proteins 0.000 description 7
• 108091092284 Homo sapiens miR-515-1 stem-loop Proteins 0.000 description 7
• 108091092278 Homo sapiens miR-515-2 stem-loop Proteins 0.000 description 7
• 108091068856 Homo sapiens miR-98 stem-loop Proteins 0.000 description 7
• 241000699660 Mus musculus Species 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 230000008859 change Effects 0.000 description 7
• 230000006870 function Effects 0.000 description 7
• 239000007943 implant Substances 0.000 description 7
• 230000035772 mutation Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• 230000003612 virological effect Effects 0.000 description 7
• 108091070511 Homo sapiens let-7c stem-loop Proteins 0.000 description 6
• 108091069046 Homo sapiens let-7g stem-loop Proteins 0.000 description 6
• 108091068853 Homo sapiens miR-100 stem-loop Proteins 0.000 description 6
• 108091067617 Homo sapiens miR-139 stem-loop Proteins 0.000 description 6
• 108091092238 Homo sapiens miR-146b stem-loop Proteins 0.000 description 6
• 108091068955 Homo sapiens miR-154 stem-loop Proteins 0.000 description 6
• 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 description 6
• 108091067580 Homo sapiens miR-214 stem-loop Proteins 0.000 description 6
• 108091070494 Homo sapiens miR-22 stem-loop Proteins 0.000 description 6
• 108091065456 Homo sapiens miR-34c stem-loop Proteins 0.000 description 6
• 108091086652 Homo sapiens miR-885 stem-loop Proteins 0.000 description 6
• 108091007773 MIR100 Proteins 0.000 description 6
• 108091008065 MIR21 Proteins 0.000 description 6
• 108091007772 MIRLET7C Proteins 0.000 description 6
• 235000001014 amino acid Nutrition 0.000 description 6
• 150000001413 amino acids Chemical class 0.000 description 6
• 239000003937 drug carrier Substances 0.000 description 6
• 230000001939 inductive effect Effects 0.000 description 6
• 239000007924 injection Substances 0.000 description 6
• 238000002347 injection Methods 0.000 description 6
• 230000004048 modification Effects 0.000 description 6
• 238000012986 modification Methods 0.000 description 6
• 238000002360 preparation method Methods 0.000 description 6
• 238000006467 substitution reaction Methods 0.000 description 6
• 238000013519 translation Methods 0.000 description 6
• 108091026821 Artificial microRNA Proteins 0.000 description 5
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
• 108091070514 Homo sapiens let-7b stem-loop Proteins 0.000 description 5
• 108091067692 Homo sapiens miR-199a-1 stem-loop Proteins 0.000 description 5
• 108091067467 Homo sapiens miR-199a-2 stem-loop Proteins 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
• 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
• 150000001875 compounds Chemical class 0.000 description 5
• 238000009792 diffusion process Methods 0.000 description 5
• 239000013604 expression vector Substances 0.000 description 5
• 150000002632 lipids Chemical class 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 230000002611 ovarian Effects 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 102000005962 receptors Human genes 0.000 description 5
• 108020003175 receptors Proteins 0.000 description 5
• 239000000243 solution Substances 0.000 description 5
• 230000008685 targeting Effects 0.000 description 5
• 241001430294 unidentified retrovirus Species 0.000 description 5
• 244000105975 Antidesma platyphyllum Species 0.000 description 4
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• 108091063764 Homo sapiens miR-583 stem-loop Proteins 0.000 description 4
• 108091060481 Homo sapiens miR-758 stem-loop Proteins 0.000 description 4
• 108091034117 Oligonucleotide Proteins 0.000 description 4
• 108010029485 Protein Isoforms Proteins 0.000 description 4
• 102000001708 Protein Isoforms Human genes 0.000 description 4
• RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 230000001093 anti-cancer Effects 0.000 description 4
• 230000001580 bacterial effect Effects 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 230000033228 biological regulation Effects 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000004700 cellular uptake Effects 0.000 description 4
• 238000013270 controlled release Methods 0.000 description 4
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000003628 erosive effect Effects 0.000 description 4
• 210000002744 extracellular matrix Anatomy 0.000 description 4
• 230000030279 gene silencing Effects 0.000 description 4
• 239000001963 growth medium Substances 0.000 description 4
• UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 4
• 235000009424 haa Nutrition 0.000 description 4
• 238000002744 homologous recombination Methods 0.000 description 4
• 230000006801 homologous recombination Effects 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 239000003094 microcapsule Substances 0.000 description 4
• 238000010369 molecular cloning Methods 0.000 description 4
• 239000000346 nonvolatile oil Substances 0.000 description 4
• 230000002018 overexpression Effects 0.000 description 4
• 238000012545 processing Methods 0.000 description 4
• 230000001629 suppression Effects 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 230000004565 tumor cell growth Effects 0.000 description 4
• 238000001262 western blot Methods 0.000 description 4
• 102100026189 Beta-galactosidase Human genes 0.000 description 3
• 241000196324 Embryophyta Species 0.000 description 3
• 241000588724 Escherichia coli Species 0.000 description 3
• 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 description 3
• 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 description 3
• 101000741978 Homo sapiens Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Proteins 0.000 description 3
• 108091086975 Homo sapiens miR-297 stem-loop Proteins 0.000 description 3
• 108091065168 Homo sapiens miR-29c stem-loop Proteins 0.000 description 3
• 108091063804 Homo sapiens miR-573 stem-loop Proteins 0.000 description 3
• 206010029260 Neuroblastoma Diseases 0.000 description 3
• 101710163270 Nuclease Proteins 0.000 description 3
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
• 208000008589 Obesity Diseases 0.000 description 3
• 102000043276 Oncogene Human genes 0.000 description 3
• 108700020796 Oncogene Proteins 0.000 description 3
• 102100038633 Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 2 protein Human genes 0.000 description 3
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
• 101150036757 SPARC gene Proteins 0.000 description 3
• 108020004459 Small interfering RNA Proteins 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 239000003963 antioxidant agent Substances 0.000 description 3
• 230000006907 apoptotic process Effects 0.000 description 3
• 108010005774 beta-Galactosidase Proteins 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 210000000170 cell membrane Anatomy 0.000 description 3
• 230000009087 cell motility Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 230000003828 downregulation Effects 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 210000000981 epithelium Anatomy 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 230000004927 fusion Effects 0.000 description 3
• 210000004602 germ cell Anatomy 0.000 description 3
• 239000000017 hydrogel Substances 0.000 description 3
• 230000001976 improved effect Effects 0.000 description 3
• 238000010874 in vitro model Methods 0.000 description 3
• 230000006698 induction Effects 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 238000002372 labelling Methods 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• 108091023663 let-7 stem-loop Proteins 0.000 description 3
• 108091063478 let-7-1 stem-loop Proteins 0.000 description 3
• 108091049777 let-7-2 stem-loop Proteins 0.000 description 3
• 210000004962 mammalian cell Anatomy 0.000 description 3
• 239000004005 microsphere Substances 0.000 description 3
• 239000002853 nucleic acid probe Substances 0.000 description 3
• 235000020824 obesity Nutrition 0.000 description 3
• 238000011275 oncology therapy Methods 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 230000001177 retroviral effect Effects 0.000 description 3
• 150000003839 salts Chemical class 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 210000002966 serum Anatomy 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000002904 solvent Substances 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000002560 therapeutic procedure Methods 0.000 description 3
• 230000004614 tumor growth Effects 0.000 description 3
• 230000003827 upregulation Effects 0.000 description 3
• 239000003981 vehicle Substances 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
• 108091006112 ATPases Proteins 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
• 229930024421 Adenine Natural products 0.000 description 2
• 102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
• 108010088751 Albumins Proteins 0.000 description 2
• 102000009027 Albumins Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 description 2
• 108090000943 Cholesterol 7-alpha-monooxygenases Proteins 0.000 description 2
• 102000004410 Cholesterol 7-alpha-monooxygenases Human genes 0.000 description 2
• 208000006332 Choriocarcinoma Diseases 0.000 description 2
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
• 241000701022 Cytomegalovirus Species 0.000 description 2
• 108010092160 Dactinomycin Proteins 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 206010014733 Endometrial cancer Diseases 0.000 description 2
• 206010014759 Endometrial neoplasm Diseases 0.000 description 2
• 102400000686 Endothelin-1 Human genes 0.000 description 2
• 101800004490 Endothelin-1 Proteins 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• 102100028122 Forkhead box protein P1 Human genes 0.000 description 2
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
• 206010018462 Glycogen storage disease type V Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 description 2
• 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 2
• 101001111338 Homo sapiens Neurofilament heavy polypeptide Proteins 0.000 description 2
• 101000603386 Homo sapiens Neuropeptide Y receptor type 1 Proteins 0.000 description 2
• 101000848718 Homo sapiens Rap guanine nucleotide exchange factor 5 Proteins 0.000 description 2
• 101000850434 Homo sapiens V-type proton ATPase subunit B, brain isoform Proteins 0.000 description 2
• 241000725303 Human immunodeficiency virus Species 0.000 description 2
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
• 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 2
• 101710041042 KIAA0825 Proteins 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• 208000008839 Kidney Neoplasms Diseases 0.000 description 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
• 239000012097 Lipofectamine 2000 Substances 0.000 description 2
• 102100024007 Neurofilament heavy polypeptide Human genes 0.000 description 2
• 102100038878 Neuropeptide Y receptor type 1 Human genes 0.000 description 2
• 108091005461 Nucleic proteins Proteins 0.000 description 2
• 241000282577 Pan troglodytes Species 0.000 description 2
• 241001631646 Papillomaviridae Species 0.000 description 2
• 235000019483 Peanut oil Nutrition 0.000 description 2
• 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
• 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
• 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
• 102100034590 Rap guanine nucleotide exchange factor 5 Human genes 0.000 description 2
• 206010038389 Renal cancer Diseases 0.000 description 2
• 108010083644 Ribonucleases Proteins 0.000 description 2
• 102000006382 Ribonucleases Human genes 0.000 description 2
• 241000714474 Rous sarcoma virus Species 0.000 description 2
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
• 229930182558 Sterol Natural products 0.000 description 2
• 102100033632 Tropomyosin alpha-1 chain Human genes 0.000 description 2
• 101710128188 Tropomyosin alpha-1 chain Proteins 0.000 description 2
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
• 102100027881 Tumor protein 63 Human genes 0.000 description 2
• 101710140697 Tumor protein 63 Proteins 0.000 description 2
• 102100025706 Uncharacterized protein KIAA0825 Human genes 0.000 description 2
• 101710100170 Unknown protein Proteins 0.000 description 2
• 102100033476 V-type proton ATPase subunit B, brain isoform Human genes 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
• 208000024248 Vascular System injury Diseases 0.000 description 2
• 208000012339 Vascular injury Diseases 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 229960000643 adenine Drugs 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 238000010171 animal model Methods 0.000 description 2
• 239000003242 anti bacterial agent Substances 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 239000002246 antineoplastic agent Substances 0.000 description 2
• 229940041181 antineoplastic drug Drugs 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 2
• 230000009286 beneficial effect Effects 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 210000000481 breast Anatomy 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000004067 bulking agent Substances 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 239000013592 cell lysate Substances 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 239000002738 chelating agent Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 210000001072 colon Anatomy 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 210000000448 cultured tumor cell Anatomy 0.000 description 2
• 229940104302 cytosine Drugs 0.000 description 2
• 229960000640 dactinomycin Drugs 0.000 description 2
• 230000007423 decrease Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 229940039227 diagnostic agent Drugs 0.000 description 2
• 239000000032 diagnostic agent Substances 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000012377 drug delivery Methods 0.000 description 2
• 238000004520 electroporation Methods 0.000 description 2
• 229940088598 enzyme Drugs 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• DLKYYJFLRUUGHJ-SSJCJZGYSA-A fomivirsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([S-])(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)C1 DLKYYJFLRUUGHJ-SSJCJZGYSA-A 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 238000001502 gel electrophoresis Methods 0.000 description 2
• 230000009368 gene silencing by RNA Effects 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 239000003102 growth factor Substances 0.000 description 2
• 229960001330 hydroxycarbamide Drugs 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 108010019691 inhibin beta A subunit Proteins 0.000 description 2
• 102000028416 insulin-like growth factor binding Human genes 0.000 description 2
• 108091022911 insulin-like growth factor binding Proteins 0.000 description 2
• 230000010354 integration Effects 0.000 description 2
• 201000010982 kidney cancer Diseases 0.000 description 2
• 238000011005 laboratory method Methods 0.000 description 2
• 239000003446 ligand Substances 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 210000005265 lung cell Anatomy 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 210000003712 lysosome Anatomy 0.000 description 2
• 230000001868 lysosomic effect Effects 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 239000002609 medium Substances 0.000 description 2
• 201000001441 melanoma Diseases 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000003584 mesangial cell Anatomy 0.000 description 2
• 229960000485 methotrexate Drugs 0.000 description 2
• POULHZVOKOAJMA-UHFFFAOYSA-N methyl undecanoic acid Chemical group CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
• 239000011859 microparticle Substances 0.000 description 2
• 229940046166 oligodeoxynucleotide Drugs 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 210000001672 ovary Anatomy 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000000312 peanut oil Substances 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 239000008194 pharmaceutical composition Substances 0.000 description 2
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
• 230000008488 polyadenylation Effects 0.000 description 2
• 229920001223 polyethylene glycol Polymers 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• 238000001556 precipitation Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 230000001737 promoting effect Effects 0.000 description 2
• 239000003380 propellant Substances 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• 150000003230 pyrimidines Chemical class 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 238000003127 radioimmunoassay Methods 0.000 description 2
• 239000011347 resin Substances 0.000 description 2
• 229920005989 resin Polymers 0.000 description 2
• 238000002741 site-directed mutagenesis Methods 0.000 description 2
• 208000000649 small cell carcinoma Diseases 0.000 description 2
• 229910001415 sodium ion Inorganic materials 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 150000003432 sterols Chemical class 0.000 description 2
• 235000003702 sterols Nutrition 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• 239000012730 sustained-release form Substances 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 238000004809 thin layer chromatography Methods 0.000 description 2
• WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
• 238000010361 transduction Methods 0.000 description 2
• 230000026683 transduction Effects 0.000 description 2
• 230000032258 transport Effects 0.000 description 2
• 230000009452 underexpressoin Effects 0.000 description 2
• 241000701161 unidentified adenovirus Species 0.000 description 2
• 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
• FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
• HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
• DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
• GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
• MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 1
• ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• 108020005065 3' Flanking Region Proteins 0.000 description 1
• KCURWTAZOZXKSJ-JBMRGDGGSA-N 4-amino-1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one;hydron;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 KCURWTAZOZXKSJ-JBMRGDGGSA-N 0.000 description 1
• 108020005029 5' Flanking Region Proteins 0.000 description 1
• 108020003589 5' Untranslated Regions Proteins 0.000 description 1
• 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
• LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
• RYYIULNRIVUMTQ-UHFFFAOYSA-N 6-chloroguanine Chemical compound NC1=NC(Cl)=C2N=CNC2=N1 RYYIULNRIVUMTQ-UHFFFAOYSA-N 0.000 description 1
• KABRXLINDSPGDF-UHFFFAOYSA-N 7-bromoisoquinoline Chemical compound C1=CN=CC2=CC(Br)=CC=C21 KABRXLINDSPGDF-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
• 108010051457 Acid Phosphatase Proteins 0.000 description 1
• 102000013563 Acid Phosphatase Human genes 0.000 description 1
• 102000055025 Adenosine deaminases Human genes 0.000 description 1
• 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
• 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 229920000936 Agarose Polymers 0.000 description 1
• 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
• 239000004382 Amylase Substances 0.000 description 1
• 102000013142 Amylases Human genes 0.000 description 1
• 108010065511 Amylases Proteins 0.000 description 1
• 108020005544 Antisense RNA Proteins 0.000 description 1
• 239000000592 Artificial Cell Substances 0.000 description 1
• 102000015790 Asparaginase Human genes 0.000 description 1
• 108010024976 Asparaginase Proteins 0.000 description 1
• 244000063299 Bacillus subtilis Species 0.000 description 1
• 235000014469 Bacillus subtilis Nutrition 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 108091032955 Bacterial small RNA Proteins 0.000 description 1
• 108010006654 Bleomycin Proteins 0.000 description 1
• 206010005949 Bone cancer Diseases 0.000 description 1
• 208000018084 Bone neoplasm Diseases 0.000 description 1
• 208000013165 Bowen disease Diseases 0.000 description 1
• 208000019337 Bowen disease of the skin Diseases 0.000 description 1
• 238000007809 Boyden Chamber assay Methods 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• 108010074051 C-Reactive Protein Proteins 0.000 description 1
• 102100032752 C-reactive protein Human genes 0.000 description 1
• FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
• 208000004434 Calcinosis Diseases 0.000 description 1
• 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
• 102100035371 Chymotrypsin-like elastase family member 1 Human genes 0.000 description 1
• 101710138848 Chymotrypsin-like elastase family member 1 Proteins 0.000 description 1
• 102100037529 Coagulation factor V Human genes 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 108010022452 Collagen Type I Proteins 0.000 description 1
• 102000012422 Collagen Type I Human genes 0.000 description 1
• 102000003712 Complement factor B Human genes 0.000 description 1
• 108090000056 Complement factor B Proteins 0.000 description 1
• 102000004420 Creatine Kinase Human genes 0.000 description 1
• 108010042126 Creatine kinase Proteins 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
• GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
• 241000702421 Dependoparvovirus Species 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 102100039922 E3 ISG15-protein ligase HERC5 Human genes 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 101710099240 Elastase-1 Proteins 0.000 description 1
• 108010042407 Endonucleases Proteins 0.000 description 1
• 102000004533 Endonucleases Human genes 0.000 description 1
• 108700039887 Essential Genes Proteins 0.000 description 1
• 201000008808 Fibrosarcoma Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• 108090000852 Forkhead Transcription Factors Proteins 0.000 description 1
• 102000004315 Forkhead Transcription Factors Human genes 0.000 description 1
• 102100029346 Forkhead box protein S1 Human genes 0.000 description 1
• 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 1
• 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 1
• 101710113436 GTPase KRas Proteins 0.000 description 1
• 102100028652 Gamma-enolase Human genes 0.000 description 1
• 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
• 101710103262 Glandular kallikrein Proteins 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 208000022461 Glomerular disease Diseases 0.000 description 1
• 208000032000 Glycogen storage disease due to muscle glycogen phosphorylase deficiency Diseases 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 102100021186 Granulysin Human genes 0.000 description 1
• 102000001398 Granzyme Human genes 0.000 description 1
• 108060005986 Granzyme Proteins 0.000 description 1
• 102100030385 Granzyme B Human genes 0.000 description 1
• 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101000946384 Homo sapiens Alpha-lactalbumin Proteins 0.000 description 1
• 101000942118 Homo sapiens C-reactive protein Proteins 0.000 description 1
• 101001027836 Homo sapiens Coagulation factor V Proteins 0.000 description 1
• 101001035145 Homo sapiens E3 ISG15-protein ligase HERC5 Proteins 0.000 description 1
• 101001062403 Homo sapiens Forkhead box protein S1 Proteins 0.000 description 1
• 101001040751 Homo sapiens Granulysin Proteins 0.000 description 1
• 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
• 101000840558 Homo sapiens Hexokinase-4 Proteins 0.000 description 1
• 101000854886 Homo sapiens Immunoglobulin iota chain Proteins 0.000 description 1
• 101001027190 Homo sapiens Kelch-like protein 42 Proteins 0.000 description 1
• 101001039157 Homo sapiens Leucine-rich repeat-containing protein 25 Proteins 0.000 description 1
• 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 1
• 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000756805 Homo sapiens Repulsive guidance molecule B Proteins 0.000 description 1
• 101000766306 Homo sapiens Serotransferrin Proteins 0.000 description 1
• 101000831940 Homo sapiens Stathmin Proteins 0.000 description 1
• 101000844507 Homo sapiens Transient receptor potential cation channel subfamily M member 2 Proteins 0.000 description 1
• 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 1
• 108091070398 Homo sapiens miR-29a stem-loop Proteins 0.000 description 1
• 108091068837 Homo sapiens miR-29b-1 stem-loop Proteins 0.000 description 1
• 108091068845 Homo sapiens miR-29b-2 stem-loop Proteins 0.000 description 1
• 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
• 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
• 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
• 206010020880 Hypertrophy Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 102100020744 Immunoglobulin iota chain Human genes 0.000 description 1
• UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
• 229930010555 Inosine Natural products 0.000 description 1
• 102100040018 Interferon alpha-2 Human genes 0.000 description 1
• 108010047761 Interferon-alpha Proteins 0.000 description 1
• 102000006992 Interferon-alpha Human genes 0.000 description 1
• 108010079944 Interferon-alpha2b Proteins 0.000 description 1
• 102100027355 Interferon-induced protein with tetratricopeptide repeats 1 Human genes 0.000 description 1
• 101710166699 Interferon-induced protein with tetratricopeptide repeats 1 Proteins 0.000 description 1
• 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 1
• 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 1
• 102000000588 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102100037641 Kelch-like protein 42 Human genes 0.000 description 1
• 241000235649 Kluyveromyces Species 0.000 description 1
• 101150105104 Kras gene Proteins 0.000 description 1
• 241000254158 Lampyridae Species 0.000 description 1
• 206010023825 Laryngeal cancer Diseases 0.000 description 1
• 208000018142 Leiomyosarcoma Diseases 0.000 description 1
• 102100040695 Leucine-rich repeat-containing protein 25 Human genes 0.000 description 1
• 108010000817 Leuprolide Proteins 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 206010027454 Metastases to breast Diseases 0.000 description 1
• 102000009664 Microtubule-Associated Proteins Human genes 0.000 description 1
• 108010020004 Microtubule-Associated Proteins Proteins 0.000 description 1
• 229930192392 Mitomycin Natural products 0.000 description 1
• 241000713869 Moloney murine leukemia virus Species 0.000 description 1
• 241000713333 Mouse mammary tumor virus Species 0.000 description 1
• 241000204795 Muraena helena Species 0.000 description 1
• 101100478241 Mus musculus Sparc gene Proteins 0.000 description 1
• 108091027869 Mus musculus miR-674 stem-loop Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
• 102100034431 Nebulette Human genes 0.000 description 1
• 101710113660 Nebulette Proteins 0.000 description 1
• 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
• 208000009869 Neu-Laxova syndrome Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
• 108010016076 Octreotide Proteins 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• 208000010191 Osteitis Deformans Diseases 0.000 description 1
• 108010077077 Osteonectin Proteins 0.000 description 1
• 102000009890 Osteonectin Human genes 0.000 description 1
• XAFYCPTXURWXGH-UHFFFAOYSA-N P(O)(O)(O)=S.P(O)(O)=O Chemical compound P(O)(O)(O)=S.P(O)(O)=O XAFYCPTXURWXGH-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 208000027868 Paget disease Diseases 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 102100026187 Placenta-specific gene 8 protein Human genes 0.000 description 1
• 101710146232 Placenta-specific gene 8 protein Proteins 0.000 description 1
• 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 1
• 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920000954 Polyglycolide Polymers 0.000 description 1
• 108010039918 Polylysine Proteins 0.000 description 1
• 241001505332 Polyomavirus sp. Species 0.000 description 1
• 229920001710 Polyorthoester Polymers 0.000 description 1
• 241000288906 Primates Species 0.000 description 1
• WDVSHHCDHLJJJR-UHFFFAOYSA-N Proflavine Chemical compound C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21 WDVSHHCDHLJJJR-UHFFFAOYSA-N 0.000 description 1
• 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
• 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
• 102100038358 Prostate-specific antigen Human genes 0.000 description 1
• 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
• 101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
• KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
• 102000013009 Pyruvate Kinase Human genes 0.000 description 1
• 108020005115 Pyruvate Kinase Proteins 0.000 description 1
• 102000009572 RNA Polymerase II Human genes 0.000 description 1
• 108010009460 RNA Polymerase II Proteins 0.000 description 1
• 108020005093 RNA Precursors Proteins 0.000 description 1
• 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
• 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
• 238000011530 RNeasy Mini Kit Methods 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 208000006265 Renal cell carcinoma Diseases 0.000 description 1
• 206010038468 Renal hypertrophy Diseases 0.000 description 1
• 102100022814 Repulsive guidance molecule B Human genes 0.000 description 1
• 102000003661 Ribonuclease III Human genes 0.000 description 1
• 108010057163 Ribonuclease III Proteins 0.000 description 1
• PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
• 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
• 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 229920002684 Sepharose Polymers 0.000 description 1
• 102000003838 Sialyltransferases Human genes 0.000 description 1
• 108090000141 Sialyltransferases Proteins 0.000 description 1
• 241000700584 Simplexvirus Species 0.000 description 1
• 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
• 206010041067 Small cell lung cancer Diseases 0.000 description 1
• 102100024237 Stathmin Human genes 0.000 description 1
• 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
• 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 description 1
• FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
• 102000007614 Thrombospondin 1 Human genes 0.000 description 1
• 108010046722 Thrombospondin 1 Proteins 0.000 description 1
• 102000006601 Thymidine Kinase Human genes 0.000 description 1
• 108020004440 Thymidine kinase Proteins 0.000 description 1
• 102100031234 Transient receptor potential cation channel subfamily M member 2 Human genes 0.000 description 1
• 208000006593 Urologic Neoplasms Diseases 0.000 description 1
• 208000002495 Uterine Neoplasms Diseases 0.000 description 1
• 102000003848 Uteroglobin Human genes 0.000 description 1
• 108090000203 Uteroglobin Proteins 0.000 description 1
• 241000700618 Vaccinia virus Species 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 108020000999 Viral RNA Proteins 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 108010031318 Vitronectin Proteins 0.000 description 1
• 102100035140 Vitronectin Human genes 0.000 description 1
• 208000008383 Wilms tumor Diseases 0.000 description 1
• 206010052428 Wound Diseases 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 229940028652 abraxane Drugs 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000001251 acridines Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000009956 adenocarcinoma Diseases 0.000 description 1
• 230000001919 adrenal effect Effects 0.000 description 1
• 230000002411 adverse Effects 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 230000002152 alkylating effect Effects 0.000 description 1
• HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
• 229960000473 altretamine Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• HSTJJKALJLWLBR-UHFFFAOYSA-N aminophosphonic acid;2-methoxyethoxyphosphonamidic acid Chemical compound NP(O)(O)=O.COCCOP(N)(O)=O HSTJJKALJLWLBR-UHFFFAOYSA-N 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• 235000019418 amylase Nutrition 0.000 description 1
• 210000004102 animal cell Anatomy 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 229940027998 antiseptic and disinfectant acridine derivative Drugs 0.000 description 1
• 239000008365 aqueous carrier Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 125000003118 aryl group Chemical group 0.000 description 1
• 229960003272 asparaginase Drugs 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000000022 bacteriostatic agent Substances 0.000 description 1
• 208000003373 basosquamous carcinoma Diseases 0.000 description 1
• 238000003573 beta galactosidase reporter gene assay Methods 0.000 description 1
• 108010087173 bile salt-stimulated lipase Proteins 0.000 description 1
• 201000009036 biliary tract cancer Diseases 0.000 description 1
• 208000020790 biliary tract neoplasm Diseases 0.000 description 1
• 238000002306 biochemical method Methods 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 229960001561 bleomycin Drugs 0.000 description 1
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229960002092 busulfan Drugs 0.000 description 1
• 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
• 102000006783 calponin Human genes 0.000 description 1
• 108010086826 calponin Proteins 0.000 description 1
• 230000004611 cancer cell death Effects 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 238000005251 capillar electrophoresis Methods 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 229960004562 carboplatin Drugs 0.000 description 1
• 231100000357 carcinogen Toxicity 0.000 description 1
• 239000003183 carcinogenic agent Substances 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 125000002091 cationic group Chemical group 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• 150000001840 cholesterol esters Chemical class 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
• 229960004316 cisplatin Drugs 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 238000012761 co-transfection Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000003240 coconut oil Substances 0.000 description 1
• 235000019864 coconut oil Nutrition 0.000 description 1
• 229940096422 collagen type i Drugs 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 239000003184 complementary RNA Substances 0.000 description 1
• 239000007891 compressed tablet Substances 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 238000011443 conventional therapy Methods 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000003431 cross linking reagent Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 230000000120 cytopathologic effect Effects 0.000 description 1
• 210000000805 cytoplasm Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 229960003901 dacarbazine Drugs 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 239000002274 desiccant Substances 0.000 description 1
• 230000000368 destabilizing effect Effects 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 1
• USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
• 210000001840 diploid cell Anatomy 0.000 description 1
• POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
• 230000006806 disease prevention Effects 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000012361 double-strand break repair Effects 0.000 description 1
• 229960004679 doxorubicin Drugs 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 238000001962 electrophoresis Methods 0.000 description 1
• 238000004945 emulsification Methods 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 230000012202 endocytosis Effects 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 230000010595 endothelial cell migration Effects 0.000 description 1
• 230000003511 endothelial effect Effects 0.000 description 1
• 238000005516 engineering process Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 238000009585 enzyme analysis Methods 0.000 description 1
• 229960001842 estramustine Drugs 0.000 description 1
• FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013613 expression plasmid Substances 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 102000033737 extracellular matrix binding proteins Human genes 0.000 description 1
• 108091009712 extracellular matrix binding proteins Proteins 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 210000005002 female reproductive tract Anatomy 0.000 description 1
• 239000010408 film Substances 0.000 description 1
• ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
• 229960000961 floxuridine Drugs 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 229960002074 flutamide Drugs 0.000 description 1
• MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
• 229960005005 fomivirsen sodium Drugs 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 238000001641 gel filtration chromatography Methods 0.000 description 1
• 238000010359 gene isolation Methods 0.000 description 1
• 238000012226 gene silencing method Methods 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 208000005017 glioblastoma Diseases 0.000 description 1
• 231100000852 glomerular disease Toxicity 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
• 201000004534 glycogen storage disease V Diseases 0.000 description 1
• XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
• 238000005469 granulation Methods 0.000 description 1
• 230000003179 granulation Effects 0.000 description 1
• 238000000227 grinding Methods 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 210000005003 heart tissue Anatomy 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
• 102000043827 human Smooth muscle Human genes 0.000 description 1
• 108700038605 human Smooth muscle Proteins 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 229910052739 hydrogen Inorganic materials 0.000 description 1
• 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
• 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 210000002865 immune cell Anatomy 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 230000003053 immunization Effects 0.000 description 1
• 238000003119 immunoblot Methods 0.000 description 1
• 230000000951 immunodiffusion Effects 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 239000011261 inert gas Substances 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000000977 initiatory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 229960003786 inosine Drugs 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 208000030776 invasive breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000004255 ion exchange chromatography Methods 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 210000002510 keratinocyte Anatomy 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 201000008627 kidney hypertrophy Diseases 0.000 description 1
• 206010023841 laryngeal neoplasm Diseases 0.000 description 1
• 238000002386 leaching Methods 0.000 description 1
• 108091007423 let-7b Proteins 0.000 description 1
• 108091063986 let-7f stem-loop Proteins 0.000 description 1
• 108091007427 let-7g Proteins 0.000 description 1
• 108091042844 let-7i stem-loop Proteins 0.000 description 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
• 229960004338 leuprorelin Drugs 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 238000003468 luciferase reporter gene assay Methods 0.000 description 1
• 210000004072 lung Anatomy 0.000 description 1
• 238000012792 lyophilization process Methods 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000027202 mammary Paget disease Diseases 0.000 description 1
• 238000005259 measurement Methods 0.000 description 1
• 229960004961 mechlorethamine Drugs 0.000 description 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
• 230000007721 medicinal effect Effects 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 1
• 229960004635 mesna Drugs 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 150000002739 metals Chemical class 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• 208000037819 metastatic cancer Diseases 0.000 description 1
• 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 108091028606 miR-1 stem-loop Proteins 0.000 description 1
• 108091023455 miR-297 stem-loop Proteins 0.000 description 1
• 108091079013 miR-34b Proteins 0.000 description 1
• 108091084018 miR-34b stem-loop Proteins 0.000 description 1
• 108091063470 miR-34b-1 stem-loop Proteins 0.000 description 1
• 108091049916 miR-34b-2 stem-loop Proteins 0.000 description 1
• 108091057222 miR-34b-3 stem-loop Proteins 0.000 description 1
• 108091092639 miR-34b-4 stem-loop Proteins 0.000 description 1
• 108091086245 miR-517b stem-loop Proteins 0.000 description 1
• 108091043460 miR-517b-1 stem-loop Proteins 0.000 description 1
• 108091044088 miR-517b-2 stem-loop Proteins 0.000 description 1
• 108091058526 miR-573 stem-loop Proteins 0.000 description 1
• 108091059494 miR-583 stem-loop Proteins 0.000 description 1
• 108091023818 miR-7 stem-loop Proteins 0.000 description 1
• 108091080296 miR-758 stem-loop Proteins 0.000 description 1
• 108091007422 miR-98 Proteins 0.000 description 1
• 238000010208 microarray analysis Methods 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000033607 mismatch repair Effects 0.000 description 1
• 229960003539 mitoguazone Drugs 0.000 description 1
• MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 201000008026 nephroblastoma Diseases 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 201000011682 nervous system cancer Diseases 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 108091027963 non-coding RNA Proteins 0.000 description 1
• 102000042567 non-coding RNA Human genes 0.000 description 1
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 238000007899 nucleic acid hybridization Methods 0.000 description 1
• 238000001216 nucleic acid method Methods 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• 235000015097 nutrients Nutrition 0.000 description 1
• 229960002700 octreotide Drugs 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 239000006186 oral dosage form Substances 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000009057 passive transport Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
• 229960002340 pentostatin Drugs 0.000 description 1
• FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
• 210000004786 perivascular cell Anatomy 0.000 description 1
• 239000012466 permeate Substances 0.000 description 1
• 239000000825 pharmaceutical preparation Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
• DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
• 150000008300 phosphoramidites Chemical class 0.000 description 1
• 150000003014 phosphoric acid esters Chemical class 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 229920001610 polycaprolactone Polymers 0.000 description 1
• 239000004632 polycaprolactone Substances 0.000 description 1
• 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
• 239000004633 polyglycolic acid Substances 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 229920000656 polylysine Polymers 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001451 polypropylene glycol Polymers 0.000 description 1
• 238000010837 poor prognosis Methods 0.000 description 1
• 230000001124 posttranscriptional effect Effects 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 230000001566 pro-viral effect Effects 0.000 description 1
• 229960000624 procarbazine Drugs 0.000 description 1
• CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
• 229960000286 proflavine Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 210000001236 prokaryotic cell Anatomy 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical class C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 238000002601 radiography Methods 0.000 description 1
• 238000002708 random mutagenesis Methods 0.000 description 1
• 238000003753 real-time PCR Methods 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 206010038038 rectal cancer Diseases 0.000 description 1
• 201000001275 rectum cancer Diseases 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 239000003488 releasing hormone Substances 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000010076 replication Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000008458 response to injury Effects 0.000 description 1
• 108091008146 restriction endonucleases Proteins 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 102200006539 rs121913529 Human genes 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 229960003440 semustine Drugs 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000000392 somatic effect Effects 0.000 description 1
• 238000002798 spectrophotometry method Methods 0.000 description 1
• 235000013599 spices Nutrition 0.000 description 1
• 206010041823 squamous cell carcinoma Diseases 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 229960001052 streptozocin Drugs 0.000 description 1
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 150000008163 sugars Chemical class 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 239000004094 surface-active agent Substances 0.000 description 1
• 206010042863 synovial sarcoma Diseases 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
• 229960003454 tamoxifen citrate Drugs 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 230000004797 therapeutic response Effects 0.000 description 1
• 230000008719 thickening Effects 0.000 description 1
• 239000002562 thickening agent Substances 0.000 description 1
• VOVUARRWDCVURC-UHFFFAOYSA-N thiirane Chemical compound C1CS1 VOVUARRWDCVURC-UHFFFAOYSA-N 0.000 description 1
• OFBPGACXRPVDQW-UHFFFAOYSA-N thiirane 1,1-dioxide Chemical compound O=S1(=O)CC1 OFBPGACXRPVDQW-UHFFFAOYSA-N 0.000 description 1
• 229960001196 thiotepa Drugs 0.000 description 1
• 208000030829 thyroid gland adenocarcinoma Diseases 0.000 description 1
• 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000005030 transcription termination Effects 0.000 description 1
• 230000037317 transdermal delivery Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009752 translational inhibition Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
• 241001529453 unidentified herpesvirus Species 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 206010046766 uterine cancer Diseases 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 210000003556 vascular endothelial cell Anatomy 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• KDQAABAKXDWYSZ-PNYVAJAMSA-N vinblastine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 KDQAABAKXDWYSZ-PNYVAJAMSA-N 0.000 description 1
• 229960004982 vinblastine sulfate Drugs 0.000 description 1
• AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
• 229960002110 vincristine sulfate Drugs 0.000 description 1
• 229960005212 vindesine sulfate Drugs 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 238000012447 xenograft mouse model Methods 0.000 description 1
• 210000005253 yeast cell Anatomy 0.000 description 1